Search

Your search keyword '"Badve, Sunil S."' showing total 384 results
Start Over Author "Badve, Sunil S."
384 results on '"Badve, Sunil S."'

2. Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study

Author

Acs, Balazs, Leung, Samuel CY, Kidwell, Kelley M, Arun, Indu, Augulis, Renaldas, Badve, Sunil S, Bai, Yalai, Bane, Anita L, Bartlett, John MS, Bayani, Jane, Bigras, Gilbert, Blank, Annika, Buikema, Henk, Chang, Martin C, Dietz, Robin L, Dodson, Andrew, Fineberg, Susan, Focke, Cornelia M, Gao, Dongxia, Gown, Allen M, Gutierrez, Carolina, Hartman, Johan, Kos, Zuzana, Lænkholm, Anne-Vibeke, Laurinavicius, Arvydas, Levenson, Richard M, Mahboubi-Ardakani, Rustin, Mastropasqua, Mauro G, Nofech-Mozes, Sharon, Osborne, C Kent, Penault-Llorca, Frédérique M, Piper, Tammy, Quintayo, Mary Anne, Rau, Tilman T, Reinhard, Stefan, Robertson, Stephanie, Salgado, Roberto, Sugie, Tomoharu, van der Vegt, Bert, Viale, Giuseppe, Zabaglo, Lila A, Hayes, Daniel F, Dowsett, Mitch, Nielsen, Torsten O, and Rimm, David L

Subjects
Cancer, Clinical Research, Breast Cancer, Biomarkers, Tumor, Biopsy, Breast Neoplasms, Female, Humans, Image Processing, Computer-Assisted, Immunohistochemistry, Ki-67 Antigen, Receptors, Estrogen, International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group, Medical and Health Sciences, Pathology
Abstract

Ki67 has potential clinical importance in breast cancer but has yet to see broad acceptance due to inter-laboratory variability. Here we tested an open source and calibrated automated digital image analysis (DIA) platform to: (i) investigate the comparability of Ki67 measurement across corresponding core biopsy and resection specimen cases, and (ii) assess section to section differences in Ki67 scoring. Two sets of 60 previously stained slides containing 30 core-cut biopsy and 30 corresponding resection specimens from 30 estrogen receptor-positive breast cancer patients were sent to 17 participating labs for automated assessment of average Ki67 expression. The blocks were centrally cut and immunohistochemically (IHC) stained for Ki67 (MIB-1 antibody). The QuPath platform was used to evaluate tumoral Ki67 expression. Calibration of the DIA method was performed as in published studies. A guideline for building an automated Ki67 scoring algorithm was sent to participating labs. Very high correlation and no systematic error (p = 0.08) was found between consecutive Ki67 IHC sections. Ki67 scores were higher for core biopsy slides compared to paired whole sections from resections (p ≤ 0.001; median difference: 5.31%). The systematic discrepancy between core biopsy and corresponding whole sections was likely due to pre-analytical factors (tissue handling, fixation). Therefore, Ki67 IHC should be tested on core biopsy samples to best reflect the biological status of the tumor.

Published
2022

7. High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma

Author

Robert, Marie E., Rüschoff, Josef, Jasani, Bharat, Graham, Rondell P., Badve, Sunil S., Rodriguez-Justo, Manuel, Kodach, Liudmila L., Srivastava, Amitabh, Wang, Hanlin L., Tang, Laura H., Troncone, Giancarlo, Rojo, Federico, Van Treeck, Benjamin J., Pratt, James, Shnitsar, Iryna, Kumar, George, Karasarides, Maria, and Anders, Robert A.

Published
2023
Full Text
View/download PDF

12. Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival.

Author

Sparano, Joseph A., Crager, Michael, Gray, Robert J., Tang, Gong, Hoag, Jess, Baehner, Frederick L., Shak, Steven, Makower, Della F., Albain, Kathy S., Hayes, Daniel F., Geyer Jr., Charles E., Dees, Elizabeth C., Goetz, Matthew P., Olson Jr., John A., Lively, Tracy, Badve, Sunil S., Saphner, Thomas J., Whelan, Timothy J., Kaklamani, Virginia G., and Wolmark, Norman

Subjects
BREAST cancer prognosis, RISK assessment, BIOLOGICAL models, CANCER relapse, GENOMICS, BREAST tumors, CHI-squared test, DESCRIPTIVE statistics, LONGITUDINAL method, SURVIVAL analysis (Biometry), TUMOR classification, COMPARATIVE studies, CONFIDENCE intervals, PROPORTIONAL hazards models, OVERALL survival, DISEASE risk factors
Abstract

Background: The 21-gene recurrence score (RS) assay (Oncotype DX) is used to guide adjuvant chemotherapy use for patients with hormone receptor-positive, HER2 (human epidermal growth factor receptor 2)-negative, axillary node-negative breast cancer. Its role, however, in providing prognostic information for late distant recurrence when added to clinicopathologic prognostic factors is unknown. Methods: A patient-specific meta-analysis including 10,004 women enrolled in three trials was updated using extended follow-up data from TAILORx, integrating the RS with histologic grade, tumor size, and age at surgery for the RSClin tool. Cox models integrating clinicopathologic factors and the RS were compared by using likelihood ratio (LR) tests. External validation of prognosis for distant recurrence in years 0 to 10 and 5 to 10 was performed in an independent cohort of 1098 women in a real-world registry. Results: RSClin provided significantly more prognostic information than either the clinicopathologic factors (ΔLR chi-square, 86.2; P<0.001) or RS alone (ΔLR chi-square, 131.0; P<0.001). The model was prognostic in an independent cohort for distant recurrence by 10 years after diagnosis (standardized hazard ratio, 1.56; 95% confidence interval, 1.25 to 1.94), was associated with late distant recurrence risk between 5 and 10 years after diagnosis (standardized hazard ratio, 1.78; 95% confidence interval, 1.25 to 2.55), and approximated the observed 10-year distant recurrence risk (Lin concordance, 0.87) and 5- to 10-year distant recurrence risk (Lin concordance, 0.92). Conclusions: The 21-gene RS is prognostic for distant recurrence and overall survival in early breast cancer. A model integrating the 21-gene RS and clinicopathologic factors improved estimates of distant recurrence risk compared with either used individually and stratified late distant recurrence risk. (Funded by the National Cancer Institute, National Institutes of Health [U10CA180820, U10CA180794, UG1CA189859, U10CA180868, and U10CA180822] and others.) [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy.

Author

Geurts, Veerle C. M., Balduzzi, Sara, Steenbruggen, Tessa G., Linn, Sabine C., Siesling, Sabine, Badve, Sunil S., DeMichele, Angela, Ignatiadis, Michail, Leon-Ferre, Roberto A., Goetz, Matthew P., Wolff, Antonio C., Klar, Natalie, Michiels, Stefan, Loi, Sherene, Adams, Sylvia, Horlings, Hugo M., Sonke, Gabe S., Salgado, Roberto, and Kok, Marleen

Published
2024
Full Text
View/download PDF

14. Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database

Author

Padda, Sukhmani K, Yao, Xiaopan, Antonicelli, Alberto, Riess, Jonathan W, Shang, Yue, Shrager, Joseph B, Korst, Robert, Detterbeck, Frank, Huang, James, Burt, Bryan M, Wakelee, Heather A, and Badve, Sunil S

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Cancer, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Databases, Factual, Female, Humans, Male, Middle Aged, Paraneoplastic Syndromes, Retrospective Studies, Thymus Neoplasms, Young Adult, Thymic epithelial tumor, Thymoma, Thymic carcinoma, Paraneoplastic, Myasthenia gravis, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

IntroductionThymic epithelial tumors (TETs) are associated with paraneoplastic/autoimmune (PN/AI) syndromes. Myasthenia gravis is the most common PN/AI syndrome associated with TETs.MethodsThe International Thymic Malignancy Interest Group retrospective database was examined to determine (1) baseline and treatment characteristics associated with PN/AI syndromes and (2) the prognostic role of PN/AI syndromes for patients with TETs. The competing risks model was used to estimate cumulative incidence of recurrence (CIR) and the Kaplan-Meier method was used to calculate overall survival (OS). A Cox proportional hazards model was used for multivariate analysis.ResultsA total of 6670 patients with known PN/AI syndrome status from 1951 to 2012 were identified. PN/AI syndromes were associated with younger age, female sex, thymoma histologic type, earlier stage, and an increased rate of total thymectomy and complete resection status. There was a statistically significant lower CIR in the group with a PN/AI syndrome than in the group without a PN/AI syndrome (10-year CIR 17.3% versus 21.2%, respectively [p = 0.0003]). The OS was improved in the group with a PN/AI syndrome compared to the group without a PN/AI syndrome (median OS 21.6 years versus 17.0 years, respectively [hazard ratio = 0.63, 95% confidence interval: 0.54-0.74, p < 0.0001]). However, in the multivariate model for recurrence-free survival and OS, PN/AI syndrome was not an independent prognostic factor.DiscussionPreviously, there have been mixed data regarding the prognostic role of PN/AI syndromes for patients with TETs. Here, using the largest data set in the world for TETs, PN/AI syndromes were associated with favorable features (i.e., earlier stage and complete resection status) but were not an independent prognostic factor for patients with TETs.

Published
2018

25. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

Author

Amgad, Mohamed, Stovgaard, Elisabeth Specht, Balslev, Eva, Thagaard, Jeppe, Chen, Weijie, Dudgeon, Sarah, Sharma, Ashish, Kerner, Jennifer K., Denkert, Carsten, Yuan, Yinyin, AbdulJabbar, Khalid, Wienert, Stephan, Savas, Peter, Voorwerk, Leonie, Beck, Andrew H., Madabhushi, Anant, Hartman, Johan, Sebastian, Manu M., Horlings, Hugo M., Hudeček, Jan, Ciompi, Francesco, Moore, David A., Singh, Rajendra, Roblin, Elvire, Balancin, Marcelo Luiz, Mathieu, Marie-Christine, Lennerz, Jochen K., Kirtani, Pawan, Chen, I-Chun, Braybrooke, Jeremy P., Pruneri, Giancarlo, Demaria, Sandra, Adams, Sylvia, Schnitt, Stuart J., Lakhani, Sunil R., Rojo, Federico, Comerma, Laura, Badve, Sunil S., Khojasteh, Mehrnoush, Symmans, W. Fraser, Sotiriou, Christos, Gonzalez-Ericsson, Paula, Pogue-Geile, Katherine L., Kim, Rim S., Rimm, David L., Viale, Giuseppe, Hewitt, Stephen M., Bartlett, John M. S., Penault-Llorca, Frédérique, Goel, Shom, Lien, Huang-Chun, Loibl, Sibylle, Kos, Zuzana, Loi, Sherene, Hanna, Matthew G., Michiels, Stefan, Kok, Marleen, Nielsen, Torsten O., Lazar, Alexander J., Bago-Horvath, Zsuzsanna, Kooreman, Loes F. S., van der Laak, Jeroen A. W. M., Saltz, Joel, Gallas, Brandon D., Kurkure, Uday, Barnes, Michael, Salgado, Roberto, and Cooper, Lee A. D.

Published
2020
Full Text
View/download PDF

26. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Author

Kos, Zuzana, Roblin, Elvire, Kim, Rim S., Michiels, Stefan, Gallas, Brandon D., Chen, Weijie, van de Vijver, Koen K., Goel, Shom, Adams, Sylvia, Demaria, Sandra, Viale, Giuseppe, Nielsen, Torsten O., Badve, Sunil S., Symmans, W. Fraser, Sotiriou, Christos, Rimm, David L., Hewitt, Stephen, Denkert, Carsten, Loibl, Sibylle, Luen, Stephen J., Bartlett, John M. S., Savas, Peter, Pruneri, Giancarlo, Dillon, Deborah A., Cheang, Maggie Chon U., Tutt, Andrew, Hall, Jacqueline A., Kok, Marleen, Horlings, Hugo M., Madabhushi, Anant, van der Laak, Jeroen, Ciompi, Francesco, Laenkholm, Anne-Vibeke, Bellolio, Enrique, Gruosso, Tina, Fox, Stephen B., Araya, Juan Carlos, Floris, Giuseppe, Hudeček, Jan, Voorwerk, Leonie, Beck, Andrew H., Kerner, Jen, Larsimont, Denis, Declercq, Sabine, Van den Eynden, Gert, Pusztai, Lajos, Ehinger, Anna, Yang, Wentao, AbdulJabbar, Khalid, Yuan, Yinyin, Singh, Rajendra, Hiley, Crispin, Bakir, Maise al, Lazar, Alexander J., Naber, Stephen, Wienert, Stephan, Castillo, Miluska, Curigliano, Giuseppe, Dieci, Maria-Vittoria, André, Fabrice, Swanton, Charles, Reis-Filho, Jorge, Sparano, Joseph, Balslev, Eva, Chen, I-Chun, Stovgaard, Elisabeth Ida Specht, Pogue-Geile, Katherine, Blenman, Kim R. M., Penault-Llorca, Frédérique, Schnitt, Stuart, Lakhani, Sunil R., Vincent-Salomon, Anne, Rojo, Federico, Braybrooke, Jeremy P., Hanna, Matthew G., Soler-Monsó, M. Teresa, Bethmann, Daniel, Castaneda, Carlos A., Willard-Gallo, Karen, Sharma, Ashish, Lien, Huang-Chun, Fineberg, Susan, Thagaard, Jeppe, Comerma, Laura, Gonzalez-Ericsson, Paula, Brogi, Edi, Loi, Sherene, Saltz, Joel, Klaushen, Frederick, Cooper, Lee, Amgad, Mohamed, Moore, David A., and Salgado, Roberto

Published
2020
Full Text
View/download PDF

30. Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer

Author

Fusco, Nicola, Geyer, Felipe C, De Filippo, Maria R, Martelotto, Luciano G, Ng, Charlotte K Y, Piscuoglio, Salvatore, Guerini-Rocco, Elena, Schultheis, Anne M, Fuhrmann, Laetitia, Wang, Lu, Jungbluth, Achim A, Burke, Kathleen A, Lim, Raymond S, Vincent-Salomon, Anne, Bamba, Masamichi, Moritani, Suzuko, Badve, Sunil S, Ichihara, Shu, Ellis, Ian O, Reis-Filho, Jorge S, and Weigelt, Britta

Published
2016
Full Text
View/download PDF

31. Supplementary Tables 1 - 2 from Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial

Author

Schneider, Bryan P., primary, Gray, Robert J., primary, Radovich, Milan, primary, Shen, Fei, primary, Vance, Gail, primary, Li, Lang, primary, Jiang, Guanglong, primary, Miller, Kathy D., primary, Gralow, Julie R., primary, Dickler, Maura N., primary, Cobleigh, Melody A., primary, Perez, Edith A., primary, Shenkier, Tamara N., primary, Vang Nielsen, Kirsten, primary, Müller, Sven, primary, Thor, Ann, primary, Sledge, George W., primary, Sparano, Joseph A., primary, Davidson, Nancy E., primary, and Badve, Sunil S., primary

Published
2023
Full Text
View/download PDF

32. Supplemental Figures and Tables from Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer

Author

Afghahi, Anosheh, primary, Purington, Natasha, primary, Han, Summer S., primary, Desai, Manisha, primary, Pierson, Emma, primary, Mathur, Maya B., primary, Seto, Tina, primary, Thompson, Caroline A., primary, Rigdon, Joseph, primary, Telli, Melinda L., primary, Badve, Sunil S., primary, Curtis, Christina N., primary, West, Robert B., primary, Horst, Kathleen, primary, Gomez, Scarlett L., primary, Ford, James M., primary, Sledge, George W., primary, and Kurian, Allison W., primary

Published
2023
Full Text
View/download PDF

33. Predicting Breast Cancer Events in Ductal Carcinoma In Situ (DCIS) Using Generative Adversarial Network Augmented Deep Learning Model

Author

Ghose, Soumya, primary, Cho, Sanghee, additional, Ginty, Fiona, additional, McDonough, Elizabeth, additional, Davis, Cynthia, additional, Zhang, Zhanpan, additional, Mitra, Jhimli, additional, Harris, Adrian L., additional, Thike, Aye Aye, additional, Tan, Puay Hoon, additional, Gökmen-Polar, Yesim, additional, and Badve, Sunil S., additional

Published
2023
Full Text
View/download PDF

35. An international study to increase concordance in Ki67 scoring

Author

Polley, Mei-Yin C, Leung, Samuel C Y, Gao, Dongxia, Mastropasqua, Mauro G, Zabaglo, Lila A, Bartlett, John M S, McShane, Lisa M, Enos, Rebecca A, Badve, Sunil S, Bane, Anita L, Borgquist, Signe, Fineberg, Susan, Lin, Ming-Gang, Gown, Allen M, Grabau, Dorthe, Gutierrez, Carolina, Hugh, Judith C, Moriya, Takuya, Ohi, Yasuyo, Osborne, C Kent, Penault-Llorca, Frédérique M, Piper, Tammy, Porter, Peggy L, Sakatani, Takashi, Salgado, Roberto, Starczynski, Jane, Lænkholm, Anne-Vibeke, Viale, Giuseppe, Dowsett, Mitch, Hayes, Daniel F, and Nielsen, Torsten O

Published
2015
Full Text
View/download PDF

37. Erratum to High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma [Modern Pathology 36(5) (2023) 100154]

Author

Robert, Marie E., Rüschoff, Josef, Jasani, Bharat, Graham, Rondell P., Badve, Sunil S., Rodriguez-Justo, Manuel, Kodach, Liudmila L., Srivastava, Amitabh, Wang, Hanlin L., Tang, Laura H., Troncone, Giancarlo, Rojo, Federico, Van Treeck, Benjamin J., Pratt, James, Shnitsar, Iryna, Kumar, George, Karasarides, Maria, and Anders, Robert A.

Published
2023
Full Text
View/download PDF

38. Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast

Author

Badve, Sunil S., primary, Cho, Sanghee, additional, Lu, Xiaoyu, additional, Cao, Sha, additional, Ghose, Soumya, additional, Thike, Aye Aye, additional, Tan, Puay Hoon, additional, Ocal, Idris Tolgay, additional, Generali, Daniele, additional, Zanconati, Fabrizio, additional, Harris, Adrian L., additional, Ginty, Fiona, additional, and Gökmen-Polar, Yesim, additional

Published
2022
Full Text
View/download PDF

39. ITMIG Consensus Statement on the Use of the WHO Histological Classification of Thymoma and Thymic Carcinoma: Refined Definitions, Histological Criteria, and Reporting

Author

Marx, Alexander, Ströbel, Philipp, Badve, Sunil S., Chalabreysse, Lara, Chan, John K.C., Chen, Gang, de Leval, Laurence, Detterbeck, Frank, Girard, Nicolas, Huang, Jim, Kurrer, Michael O., Lauriola, Libero, Marino, Mirella, Matsuno, Yoshihiro, Molina, Thierry Jo, Mukai, Kiyoshi, Nicholson, Andrew G., Nonaka, Daisuke, Rieker, Ralf, Rosai, Juan, Ruffini, Enrico, and Travis, William D.

Published
2014
Full Text
View/download PDF

42. A predictor of response in HER2+ breast cancer—at last!

Author

Badve, Sunil S and Gökmen-Polar, Yesim

Subjects
*HER2 positive breast cancer, *HORMONE receptor positive breast cancer, *CANCER relapse, *REVERSE transcriptase polymerase chain reaction
Abstract

Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. The breast cancer world is somewhat fortunate to have biomarkers that are great at selecting patients most likely to respond to targeted therapies. In another study, Guarneri et al. ([14]) showed that HER2DX could predict response following neoadjuvant letrozole in combination with dual HER2 blockade with trastuzumab and pertuzumab in early stage HER2+ and hormone receptor-positive breast cancer. Unfortunately, the same has not been true for tumors overexpressing HER2 and for tumors lacking expression of estrogen (progesterone) and HER2 receptors (triple-negative breast cancers). [Extracted from the article]

Published
2023
Full Text
View/download PDF

44. Abstract P1-08-35: Stromal tumor infiltrating lymphocytes analysis by race and ethnicity in triple negative breast cancers from 2 phase III randomized adjuvant breast cancer trials: ECOG-ACRIN E2197 and E1199

Author

Klar, Natalie, primary, Gray, Robert J, additional, Adams, Sylvia, additional, Sparano, Joseph A, additional, Goldstein, Lori J, additional, DeMichele, Angela M, additional, Wolff, Antonio C, additional, Davidson, Nancy E, additional, Sledge, George W, additional, and Badve, Sunil S, additional

Published
2022
Full Text
View/download PDF

46. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

Author

Sparano, Joseph A., Gray, Robert J., Makower, Della F., Pritchard, Kathleen I., Albain, Kathy S., Hayes, Daniel F., Geyer, Charles E., Jr., Dees, Elizabeth C., Perez, Edith A., Olson, John A., Jr., Zujewski, JoAnne, Lively, Tracy, Badve, Sunil S., Saphner, Thomas J., Wagner, Lynne I., Whelan, Timothy J., Ellis, Matthew J., Paik, Soonmyung, Wood, William C., Ravdin, Peter, Keane, Maccon M., Gomez Moreno, Henry L., Reddy, Pavan S., Goggins, Timothy F., Mayer, Ingrid A., Brufsky, Adam M., Toppmeyer, Deborah L., Kaklamani, Virginia G., Atkins, James N., Berenberg, Jeffrey L., and Sledge, George W.

Published
2015
Full Text
View/download PDF

47. Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial)

Author

Chou, Shinn-Huey S., primary, Romanoff, Justin, additional, Lehman, Constance D., additional, Khan, Seema A., additional, Carlos, Ruth, additional, Badve, Sunil S., additional, Xiao, Jennifer, additional, Corsetti, Ralph L., additional, Javid, Sara H., additional, Spell, Derrick W., additional, Han, Linda K., additional, Sabol, Jennifer L., additional, Bumberry, John R., additional, Gareen, Ilana F., additional, Snyder, Bradley S., additional, Gatsonis, Constantine, additional, Wagner, Lynne I., additional, Wolff, Antonio C., additional, Miller, Kathy D., additional, Sparano, Joseph A., additional, Comstock, Christopher E., additional, and Rahbar, Habib, additional

Published
2021
Full Text
View/download PDF

48. A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study

Author

Mamdani, Hirva, primary, Schneider, Bryan, additional, Perkins, Susan M., additional, Burney, Heather N., additional, Kasi, Pashtoon Murtaza, additional, Abushahin, Laith I., additional, Birdas, Thomas, additional, Kesler, Kenneth, additional, Watkins, Tracy M., additional, Badve, Sunil S., additional, Radovich, Milan, additional, and Jalal, Shadia I., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results